PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
38.68%
Cash & equivalents growing 38.68% while AGEN's declined -9.45%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
38.68%
Below half of AGEN's -9.45%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.26%
Below half of AGEN's -8.75%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
101.21%
Similar yoy growth to AGEN's 92.91%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.21%
≥ 1.5x AGEN's 39.04%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Below half of AGEN's -7.53%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-44.89%
Less than half of AGEN's 128.48%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.14%
Exceeding 1.5x AGEN's 8.71%. Michael Burry suspects ballooning short-term obligations vs. competitor.
112.59%
Above 1.5x AGEN's 6.66%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
112.59%
Less than half of AGEN's -3.04%. David Dodd sees far fewer liability expansions relative to competitor.
-89.62%
Less than half of AGEN's 3.17%. David Dodd sees fewer share issuances vs. competitor.
-9.70%
≥ 1.5x AGEN's -0.90%. David Dodd sees higher yoy retained profits than competitor.
98.99%
Less than half of AGEN's -0.37%. David Dodd sees fewer intangible or market-driven swings than competitor.
100.73%
Higher Other Stockholders' Equity Items Growth compared to AGEN's zero value, indicating worse performance.
-358.06%
≥ 1.5x AGEN's -55.75%. David Dodd sees stronger capital base growth than competitor.
42.36%
Below half AGEN's -7.53%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.72%
Less than half of AGEN's 11.46%. David Dodd sees better deleveraging or stronger cash buildup than competitor.